InsidersTradesSigma
Follow the JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Market capitalisation: €15.9bn. The latest transaction was disclosed on 10 September 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: NEENA PATIL. The full history is accessible without an account.
Analysts rate JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY Buy (bullish), based on 20 analysts. Average price target: US$286.90.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
5 of 5 declarations
JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY 是一家生物制药公司，专注于开发治疗严重和罕见疾病的药物。该公司在纳斯达克上市，股票代码为 JAZZ。